Follow
Eneda Toska, PhD
Eneda Toska, PhD
Johns Hopkins University School of Medicine
Verified email at jhmi.edu
Title
Cited by
Cited by
Year
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
3382015
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
E Toska, HU Osmanbeyoglu, P Castel, C Chan, RC Hendrickson, ...
Science 355 (6331), 1324-1330, 2017
2462017
PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition
P Castel, H Ellis, R Bago, E Toska, P Razavi, FJ Carmona, S Kannan, ...
Cancer cell 30 (2), 229-242, 2016
2112016
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ...
Science 366 (6466), 714-723, 2019
2062019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ...
Nature medicine 25 (9), 1422-1427, 2019
1692019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ...
Nature medicine 25 (9), 1422-1427, 2019
1692019
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
G Xu, S Chhangawala, E Cocco, P Razavi, Y Cai, JE Otto, L Ferrando, ...
Nature genetics 52 (2), 198-207, 2020
1452020
Mechanisms of transcriptional regulation by WT1 (Wilms’ tumour 1)
E Toska, SGE Roberts
Biochemical Journal 461 (1), 15-32, 2014
1382014
Overview of the relevance of PI3K pathway in HR-positive breast cancer
N Vasan, E Toska, M Scaltriti
Annals of oncology 30, x3-x11, 2019
1262019
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ...
Cancer discovery 10 (3), 440-459, 2020
1122020
Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase
E Toska, HA Campbell, J Shandilya, SJ Goodfellow, P Shore, KF Medler, ...
Cell reports 2 (3), 462-469, 2012
902012
The present and future of PI3K inhibitors for cancer therapy
P Castel, E Toska, JA Engelman, M Scaltriti
Nature cancer 2 (6), 587-597, 2021
682021
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
E Cocco, F Javier Carmona, P Razavi, HH Won, Y Cai, V Rossi, C Chan, ...
Science signaling 11 (551), eaat9773, 2018
672018
FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer
A Arruabarrena-Aristorena, JLV Maag, S Kittane, Y Cai, WR Karthaus, ...
Cancer cell 38 (4), 534-550. e9, 2020
652020
PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression
E Toska, P Castel, S Chhangawala, A Arruabarrena-Aristorena, C Chan, ...
Cell reports 27 (1), 294-306. e5, 2019
532019
Presenilin influences glycogen synthase kinase-3 β (GSK-3β) for kinesin-1 and dynein function during axonal transport
K Dolma, GJ Iacobucci, K Hong Zheng, J Shandilya, E Toska, JA White, ...
Human molecular genetics 23 (5), 1121-1133, 2014
532014
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
P Mondello, EJ Brea, E De Stanchina, E Toska, AY Chang, M Fennell, ...
JCI insight 2 (6), 2017
462017
WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line
SJ Goodfellow, MR Rebello, E Toska, LAH Zeef, SG Rudd, KF Medler, ...
Biochemical Journal 435 (1), 113-125, 2011
462011
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ...
Molecular cancer 22 (1), 138, 2023
442023
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ...
Cancer discovery 11 (1), 126-141, 2021
382021
The system can't perform the operation now. Try again later.
Articles 1–20